Our study delineates a complete exosome-to-vasculature signaling axis and positions TAGLN2/NRP1/SEMA4D/YAP module as an integrated diagnostic and therapeutic target against metastatic GC. This evidence concerns the gene TAGLN2 and gastric cancer.